Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Operating Expenses (2016 - 2025)

Cardiff Oncology's Operating Expenses history spans 15 years, with the latest figure at $8.1 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 36.57% year-over-year to $8.1 million; the TTM value through Dec 2025 reached $49.6 million, changed 0.44%, while the annual FY2025 figure was $49.6 million, 0.44% changed from the prior year.
  • Operating Expenses for Q4 2025 was $8.1 million at Cardiff Oncology, down from $12.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $14.9 million in Q2 2025 and bottomed at $5.5 million in Q1 2021.
  • The 5-year median for Operating Expenses is $11.0 million (2023), against an average of $10.7 million.
  • The largest annual shift saw Operating Expenses surged 102.18% in 2022 before it tumbled 36.57% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $9.7 million in 2021, then fell by 1.44% to $9.5 million in 2022, then rose by 10.17% to $10.5 million in 2023, then rose by 21.3% to $12.7 million in 2024, then crashed by 36.57% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Operating Expenses are $8.1 million (Q4 2025), $12.1 million (Q3 2025), and $14.9 million (Q2 2025).